EXEL Exelixis Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: EXEL

Price (delayed)

$70.13

Market cap

$17.11B

P/E Ratio

20.33

Dividend/share

N/A

EPS

$3.45

Enterprise value

$16.97B

?
Relative Growth: Rel. Growth: 96
Relative Strength: Rel. Strength: 95
Relative Valuation: Rel. Valuation: 58
Relative Profitability: Rel. Profitability: 98

Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our ...

Highlights
The company's EPS rose by 40% YoY and by 4.9% QoQ
The company's net income rose by 31% YoY and by 2.8% QoQ
The P/E is 30% above the last 4 quarters average of 15.6 but 22% below the 5-year quarterly average of 25.9
EXEL's quick ratio is down by 15% year-on-year and by 8% since the previous quarter
The company's equity fell by 15% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.exelixis.com
Peers: MRK BMY AMGN CRIS

Key stats

What are the main financial stats of EXEL

EXEL stock price

How has the Exelixis stock price performed over time
Intraday
1.07%
1 week
7.71%
1 month
20.11%
1 year
81.36%
YTD
60%
QTD
20.07%

Financial performance

How have Exelixis's revenue and profit performed over time
Revenue
$2.5B
Gross profit
$2.4B
Operating income
$1B
Net income
$885.14M
Gross margin
96.3%
Net margin
35.5%
The company's net income rose by 31% YoY and by 2.8% QoQ
Exelixis's operating income has increased by 25% YoY and by 3.3% QoQ
The net margin has increased by 20% YoY
EXEL's operating margin is up by 15% year-on-year

Price vs fundamentals

How does EXEL's price correlate with its fundamentals

Growth

What is Exelixis's growth rate over time

Valuation

What is Exelixis stock price valuation
EXEL P/E details
P/E
20.33
P/B
9.48
P/S
6.93
EV/EBIT
15.92
EV/EBITDA
15.19
EV/Sales
6.8
The company's EPS rose by 40% YoY and by 4.9% QoQ
The P/E is 30% above the last 4 quarters average of 15.6 but 22% below the 5-year quarterly average of 25.9
EXEL's P/B is 137% above its 5-year quarterly average of 4.0 and 44% above its last 4 quarters average of 6.6
The company's equity fell by 15% YoY
EXEL's price to sales (P/S) is 61% higher than its 5-year quarterly average of 4.3 and 31% higher than its last 4 quarters average of 5.3
The revenue has grown by 9% YoY and by 2.5% from the previous quarter

Efficiency

How efficient is Exelixis business performance
The company's return on equity rose by 44% YoY and by 7% QoQ
The ROIC has grown by 42% YoY and by 7% from the previous quarter
The ROA has grown by 41% YoY and by 6% from the previous quarter
The company's return on sales rose by 12% YoY

Dividends

What is EXEL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EXEL.

Financial health

How did Exelixis financials performed over time
EXEL's quick ratio is down by 15% year-on-year and by 8% since the previous quarter
EXEL's current ratio is down by 14% year-on-year and by 7% since the previous quarter
The debt is 91% less than the equity
The company's equity fell by 15% YoY
The company's debt to equity rose by 13% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.